A Prospective, Single-arm, Exploratory Study of Triflurid... | NCT07371871 | Trialant

A Prospective, Single-arm, Exploratory Study of Triflurid... | NCT07371871 | Trialant

Arms/Interventions Module

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Trifluridine/Tipiracil (TAS-102) combined with Apatinib	Drug	TAS-102: 35 mg/m2/dose, taken orally within 1 hour after breakfast and dinner, twice daily, on days 1-5 of each cycle, followed by a 9-day drug-free interval, with 28 days constituting one cycle. Apatinib: 500 mg/dose, once daily, administered continuously for 5 days followed by a 2-day break, with 28 days as one cycle. Imaging evaluation should be performed every 2-3 cycles until disease progression or intolerance occurs.

Outcomes Module

Secondary Outcomes

Measure	Description	Time Frame
Duration of Response，DOR		From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
Progression-Free Survival，PFS		From date of first dose administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

Ancestor Terms

ID	Term
D013936	Thymidine
D011741	Pyrimidine Nucleosides
D011743	Pyrimidines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D003853	Deoxyribonucleosides
D009705	Nucleosides
D009706	Nucleic Acids, Nucleotides, and Nucleosides